临床肿瘤学杂志

• 论著 • 上一篇    下一篇

CD133在非小细胞肺癌中的表达及预后意义的Meta分析

李 丹,江 露,徐 斌,蒋敬庭,李 翀   

  1. 213003 江苏常州 苏州大学附属第三医院呼吸内科
  • 收稿日期:2013-06-08 修回日期:2013-07-28 出版日期:2013-10-31 发布日期:2013-10-31
  • 通讯作者: 李 翀

CD133 expression and prognostic significance in nonsmall cell lung cancer: a metaanalysis

LI Dan, JIANG Lu, XU Bin, JIANG Jingting, LI Chong

  

  1. Department of Respiration, the Third Affiliated Hospital of Soochow University, Changzhou 213003, China
  • Received:2013-06-08 Revised:2013-07-28 Online:2013-10-31 Published:2013-10-31

摘要: 目的 系统评价CD133在非小细胞肺癌(NSCLC)中的表达及其与预后的关系。方法 计算机检索PubMed、CBMdisc、Cochrance、CNKI、万方、维普等数据库,收集有关CD133在NSCLC中表达及临床意义的研究。检索时限均为从建库至2013年3月15日。由2名研究者按照纳入排除标准独立筛选文献,提取资料,质量评价。采用RevMan 50软件进行Meta分析。结果共纳入11个研究947例患者。Meta分析结果显示,淋巴结转移组的CD133阳性表达率高于未转移组(RR=1.33, 95%CI:1.17~1.51;P<0.0001),CD133阳性表达组的3、5年生存率低于阴性表达组(P<0.05)。不同性别、吸烟情况、病理类型、组织学分级及T分期的CD133阳性表达率的差异均无统计学意义。结论 CD133可能是NSCLC的不良预后因素。由于纳入研究的质量和数量有限,降低了本系统评价的证据强度,故本系统评价的结论仅供临床研究与实践参考。

Abstract: Objective To investigate CD133 expression in nonsmall cell lung cancer(NSCLC) and the relationship with prognosis. Methods Such databases as PubMed, CBMdisc, Cochrance, CNKI, Wanfang and Weipu database were searched from the date of their establishment to March 15th 2013 to collect the researches about CD133 expression and prognostic significance in NSCLC. According to the inclusion and exclusion criteria, two reviewers screened literature, extracted data and assessed the quality of included studies independently. Then results of metaanalysis were conducted using RevMan 5.0 software. Results A total of 11 researches involving 947 patients were included. The results of metaanalysis suggested that CD133positive rate was correlated to nodal metastasis(RR=1.33, 95%CI:1.17-1.51, P<0.0001), and CD133positive patients had low 3-and 5-year overall survival compared with CD133-negative patients(P<0.05). But CD133-positive rate was not related to gender, smoking history, pathological types, histology grading and T stage. Conclusion NSCLC patients with high expression of CD133 may have lower overall survival. The quality and quantity limitation of the included studies decrease the strength of evidence, so the conclusion of this systematic review only provides some references for clinical research and practice.

No related articles found!
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!